Cisplatin in the era of PARP inhibitors and immunotherapy.
Pharmacol Ther
; 258: 108642, 2024 Jun.
Article
en En
| MEDLINE
| ID: mdl-38614254
ABSTRACT
Platinum compounds such as cisplatin, carboplatin and oxaliplatin are widely used in chemotherapy. Cisplatin induces cytotoxic DNA damage that blocks DNA replication and gene transcription, leading to arrest of cell proliferation. Although platinum therapy alone is effective against many tumors, cancer cells can adapt to the treatment and gain resistance. The mechanisms for cisplatin resistance are complex, including low DNA damage formation, high DNA repair capacity, changes in apoptosis signaling pathways, rewired cell metabolisms, and others. Drug resistance compromises the clinical efficacy and calls for new strategies by combining cisplatin with other therapies. Exciting progress in cancer treatment, particularly development of poly (ADP-ribose) polymerase (PARP) inhibitors and immune checkpoint inhibitors, opened a new chapter to combine cisplatin with these new cancer therapies. In this Review, we discuss how platinum synergizes with PARP inhibitors and immunotherapy to bring new hope to cancer patients.
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Cisplatino
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
/
Inmunoterapia
/
Neoplasias
/
Antineoplásicos
Idioma:
En
Revista:
Pharmacol Ther
Año:
2024
Tipo del documento:
Article